Drugs / SIM0609
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07265921 | Nov 2025 → Dec 2028 expected | cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-28 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory SIM0609, Simcere Zaiming’s CDH17-targeting ADC is approved by the U.S. FDA to enter clinical trials simcere.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | Jiangsu Simcere Pharmaceutical Co., Ltd. | SIM0609 Doses First Patient in Phase I Clinical Study at Peking University Cancer Hospital simcere.com ↗ |
| 2025-09-28 | Jiangsu Simcere Pharmaceutical Co., Ltd. | SIM0609, Simcere Zaiming’s CDH17-targeting ADC is approved by the U.S. FDA to enter clinical trials simcere.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM0609 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07265921 ↗ |